BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eisai readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Eisai's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641466-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06641466)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Women When Used for 
 Intermittent Prevention of Menstrual Migraine\nEstimated primary completio
 n: 29 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06641466
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602258-665@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT06602258)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Study of E2814 With Concurrent Lecanemab Treatment in Participants With Ea
 rly Alzheimer's Disease\nEstimated primary completion: 3 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-665@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT03887455)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study to Confirm Safety and Efficacy of Lecanemab in Participants With Ear
 ly Alzheimer's Disease\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03887455
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03878849-10856@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:stenoparib: Phase 2 readout est. (NCT03878849)
DESCRIPTION:stenoparib\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  the Anti-tumor Effect of 2X-121 in Patients With Recurrent\, Advanced Ova
 rian Cancer\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/stenoparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03878849
URL:https://assetmemo.bio/drug/stenoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04078295-7635@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Eribulin mesylate: Phase 1/2 readout est. (NCT04078295)
DESCRIPTION:Eribulin mesylate\, phase 1/2.\nStudy: A Study of E7389 Liposom
 al Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/eribulin-mesylate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04078295
URL:https://assetmemo.bio/drug/eribulin-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015141-1636@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Fycompa (Perampanel): Phase 2 readout est. (NCT04015141)
DESCRIPTION:Fycompa (Perampanel)\, phase 2\, Epilepsy.\nStudy: A Study to E
 valuate Efficacy and Safety of Perampanel Administered as an Adjunctive Th
 erapy in Pediatric Participants With Childhood Epilepsy\nEstimated primary
  completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/perampanel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04015141
URL:https://assetmemo.bio/drug/perampanel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-2161@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07487519)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Phase II Study of HLX43 Monother
 apy or Combined With Immune Checkpoint Inhibitors in Patients With Locally
  Advanced\, Recurrent\, or Metastatic Triple-negative Breast Cancer.\nEsti
 mated primary completion: 15 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07487519
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2161@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07253142)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i
 n Subjects With Advanced Lung Cancer\nEstimated primary completion: 18 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253
 142
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358585-2161@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:Serplulimab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluat
 e HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Me
 tastatic Colorectal Cancer\nEstimated primary completion: 28 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-2161@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06857279)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Phase II Clinical Study to Eva
 luate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamou
 s Cell Carcinoma\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729462-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20281021
DTEND;VALUE=DATE:20281022
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT07729462)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adults When Used for
  the Prevention of Chronic Migraine\nEstimated primary completion: 21 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant-
 nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07729462
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468659-665@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT04468659)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: AH
 EAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With 
 Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevate
 d Amyloid and Also in Participants With Early Preclinical Alzheimer's Dise
 ase and Intermediate Amyloid\nEstimated primary completion: 21 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04468659
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564324-2075@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT06564324)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Pos
 itive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/taletrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06564324
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649242-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04649242)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Randomize
 d Study in Children and Adolescents With Migraine: Acute Treatment\nEstima
 ted primary completion: 9 January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04649242
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05156398-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT05156398)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Efficacy 
 and Safety Study of Rimegepant for the Preventative Treatment of Migraine 
 in Pediatric Subjects\nEstimated primary completion: 27 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05156398
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616194-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06616194)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adolescents With Fre
 quent Migraine\nEstimated primary completion: 26 February 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06616194
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743141-10363@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04743141)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Long-term
  Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment 
 of Migraine\nEstimated primary completion: 31 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04743141
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154706-2075@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT07154706)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Po
 sitive NSCLC (TRUST-IV)\nEstimated primary completion: 30 August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/taletrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07154706
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-2161@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Serplulimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
